was read the article
array:22 [ "pii" => "S2445146023000274" "issn" => "24451460" "doi" => "10.1016/j.vacune.2023.04.006" "estado" => "S300" "fechaPublicacion" => "2023-04-01" "aid" => "273" "copyright" => "Elsevier España, S.L.U.. All rights reserved" "copyrightAnyo" => "2022" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "Vacunas. 2023;24:158-9" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "itemAnterior" => array:19 [ "pii" => "S2445146023000201" "issn" => "24451460" "doi" => "10.1016/j.vacune.2023.03.002" "estado" => "S300" "fechaPublicacion" => "2023-04-01" "aid" => "276" "copyright" => "Elsevier España, S.L.U." "documento" => "article" "crossmark" => 1 "subdocumento" => "rev" "cita" => "Vacunas. 2023;24:150-7" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Review article</span>" "titulo" => "Current situation and future perspectives of vaccines against respiratory syncytial virus" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "150" "paginaFinal" => "157" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Situación actual y perspectivas de futuro de las vacunas frente al virus respiratorio sincitial" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "f0010" "etiqueta" => "Fig. 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 2012 "Ancho" => 2372 "Tamanyo" => 432335 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "al0010" "detalle" => "Fig. " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="sp0010" class="elsevierStyleSimplePara elsevierViewall">Schematic structure of RSV F-glycoprotein in its pre- and post-fusion active forms with the antigenic areas of each (modified from Graham et al.<a class="elsevierStyleCrossRef" href="#bb0035"><span class="elsevierStyleSup">7</span></a>).</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Jordi Reina, Elisa Gónzalez de Herrero" "autores" => array:2 [ 0 => array:2 [ "nombre" => "Jordi" "apellidos" => "Reina" ] 1 => array:2 [ "nombre" => "Elisa" "apellidos" => "Gónzalez de Herrero" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S1576988722001996" "doi" => "10.1016/j.vacun.2022.12.005" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1576988722001996?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2445146023000201?idApp=UINPBA00004N" "url" => "/24451460/0000002400000002/v1_202305072301/S2445146023000201/v1_202305072301/en/main.assets" ] "en" => array:12 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Letter to the Editor</span>" "titulo" => "Optic neuritis associated with COVID-19-related vaccines" "tieneTextoCompleto" => true "saludo" => "Dear Editor;" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "158" "paginaFinal" => "159" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Masoud Keikha, Mehdi Zandhaghighi, Shahram Shahraki Zahedani" "autores" => array:3 [ 0 => array:4 [ "nombre" => "Masoud" "apellidos" => "Keikha" "email" => array:1 [ 0 => "masoud.keykha90@gmail.com" ] "referencia" => array:3 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "af0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "af0010" ] 2 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cr0005" ] ] ] 1 => array:3 [ "nombre" => "Mehdi" "apellidos" => "Zandhaghighi" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "af0005" ] ] ] 2 => array:3 [ "nombre" => "Shahram Shahraki" "apellidos" => "Zahedani" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "af0005" ] ] ] ] "afiliaciones" => array:2 [ 0 => array:3 [ "entidad" => "Department of Medical Microbiology, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran" "etiqueta" => "a" "identificador" => "af0005" ] 1 => array:3 [ "entidad" => "Infectious Diseases and Tropical Medicine Research Center, Resistant Tuberculosis Institute, Zahedan University of Medical Sciences, Zahedan, Iran" "etiqueta" => "b" "identificador" => "af0010" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cr0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "textoCompleto" => "<span class="elsevierStyleSections"><p id="p0005" class="elsevierStylePara elsevierViewall">There were more than 634,754,573 COVID-19-infected cases and 6,609,414 global deaths from SARS-CoV-2 infection by November 2022, as the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic continues to spread worldwide. It is imperative in this case to create effective SARS-CoV-2 vaccinations as a strategy to lessen the severity of the illness and subsequent deaths.<a class="elsevierStyleCrossRef" href="#bb0005"><span class="elsevierStyleSup">1</span></a> Adenoviral vectors (AstraZeneca and Janssen), messenger RNA (m-RNA)-based vaccines (Pfizer and Moderna), and inactivated virus are three vaccine categories that have been approved by the World Health Organization to prevent SARS-CoV-2 illness (as Sinovac). In phase 3 randomized studies, these vaccine doses were not associated with significant adverse effects.<a class="elsevierStyleCrossRef" href="#bb0010"><span class="elsevierStyleSup">2</span></a> However, given the substantial side effects associated with COVID-19 vaccinations and the quick and extensive clinical use of these vaccines, they must be further evaluated. Another issue that continues to be difficult is the clinical effectiveness of SARS-CoV-2 vaccinations in immune-compromised people.<a class="elsevierStyleCrossRef" href="#bb0015"><span class="elsevierStyleSup">3</span></a></p><p id="p0010" class="elsevierStylePara elsevierViewall">Early observations indicate that COVID-19 infection causes ocular symptoms via both direct invasion and indirect immune-mediated processes.<a class="elsevierStyleCrossRef" href="#bb0020"><span class="elsevierStyleSup">4</span></a> In this respect, it is known that SARS-CoV-2-infected people have ocular symptoms like conjunctivitis, scleritis, orbital inflammation, keratitis, and retinal damage.<a class="elsevierStyleCrossRef" href="#bb0025"><span class="elsevierStyleSup">5</span></a> However, after receiving the COVID-19 vaccine, reports of neuro-ophthalmic symptoms have been made. The literature states that after receiving the COVID-19 vaccine, ocular issues involving the ophthalmic uvea, optic nerve, retina, orbit, cornea, and retinal vessels, as well as cranial nerve palsies (such as those affecting the oculomotor, abducens, and facial nerves), have emerged.<a class="elsevierStyleCrossRefs" href="#bb0030"><span class="elsevierStyleSup">6–8</span></a> Additionally, after receiving the SARS-CoV-2 vaccine, optic neuritis, an uncommon demyelinating effect, has been reported.</p><p id="p0015" class="elsevierStylePara elsevierViewall">Historically, following various vaccinations, central demyelinating symptoms together with additional optic neuritis, acute transverse myelitis, and even acute disseminated encephalomyelitis are frequently documented.<a class="elsevierStyleCrossRef" href="#bb0025"><span class="elsevierStyleSup">5</span></a> According to research from England, syphilis (OR: 5.76), mycoplasma (OR: 3.90), and the Epstein–Barr virus (OR: 2.3) are infectious diseases that are correlated with ocular neuritis.<a class="elsevierStyleCrossRef" href="#bb0045"><span class="elsevierStyleSup">9</span></a> However, after receiving the COVID-19 vaccine's priming dosage, there was an uncommon cluster of severe optic neuritis in UK populations, which was at odds with the epidemiological trends of the previous 22 years. According to Petzold et al.'s review of the neurological adverse effects linked to COVID-19 post-vaccination in the UK, 85 cases of optic neuritis following COVID-19 vaccination had acceptable reviews following treatment.<a class="elsevierStyleCrossRef" href="#bb0050"><span class="elsevierStyleSup">10</span></a> In Taiwan, Lee and colleagues reported the first case of optic neuritis after a second vaccination with OxfordAstraZeneca, stating that early detection and treatment may help to stop demyelinating progression in those cases<a class="elsevierStyleCrossRef" href="#bb0055"><span class="elsevierStyleSup">11</span></a>; Optic neuritis has reportedly occurred following administration of different COVID-19 vaccines, such as mRNA-1273, BNT162b2, or Ad26.COV2.S, according to the literature. Historically, influenza, anti-rabies, HPV, and other vaccines have all been linked to optic neuritis. In conclusion, vaccine-induced optic neuritis is an unfortunate side effect, but it seldom manifests.<a class="elsevierStyleCrossRef" href="#bb0060"><span class="elsevierStyleSup">12</span></a> It appears that vaccines and their adjuvants help to induce a strong immune response. As a result, ophtalmic nervous system injuries may occur following reactivation.<a class="elsevierStyleCrossRef" href="#bb0065"><span class="elsevierStyleSup">13</span></a> However, the absence of adjuvants in some of COVID-19 vaccines on the one hand, and the occurrence of autoimmune reactions (It is the same as in adjuvant-containing vaccines) on the other hand remains a mystery.<a class="elsevierStyleCrossRef" href="#bb0070"><span class="elsevierStyleSup">14</span></a> There are some indications that the COVID-19 vaccine caused anti-CD20 antibodies to be produced and elevated.<a class="elsevierStyleCrossRef" href="#bb0075"><span class="elsevierStyleSup">15</span></a> Furthermore, earlier research suggested that the susceptibility to ocular neuropathies following immunization may be due to an autoimmune mechanism. In this regard, research has demonstrated that post-vaccination optic neuropathy is linked to molecular mimicry, which causes neutralizing antibodies against the SARS-CoV-2 spike protein to cross-react with components of the central nervous system, particularly the optic nerve.<a class="elsevierStyleCrossRef" href="#bb0080"><span class="elsevierStyleSup">16</span></a> As a result, the condition may also be caused by synergistic interactions involving the autoimmune response, endothelial dysfunction, and comorbidities such as younger age, gender, diabetes, or hypertension.</p><p id="p0020" class="elsevierStylePara elsevierViewall">According to recent cohort data, there is a clear difference between COVID-19 vaccine-induced optic neuritis and prior conventional optic neuritis in terms of disease severity, bilateral presentation, age, gender, and even radiological appearances. AstraZeneca (ChAdOx1) was given to a large number of people who had no prior evidence of neuro-inflammation.<a class="elsevierStyleCrossRef" href="#bb0085"><span class="elsevierStyleSup">17</span></a> Paybast et al., 2022, recently reported six individuals with neuromyelitis optica spectrum disease who developed optic neuritis six days after receiving the COVID-19 vaccine. Two doses of the COVID-19 vaccine were administered to more than 90% of the subjects, 83.3% of whom were female and had numerous comorbid conditions (77%) prior to treatment.<a class="elsevierStyleCrossRef" href="#bb0090"><span class="elsevierStyleSup">18</span></a> The most common ophthalmic neurophaties linked to the SARS-CoV-2 vaccines were also reported by Elnahry and colleagues. They discovered that all COVID-19 vaccines can cause ophthalmic manifestations like anterior ischemic optic neuropathy (AION), optic neuritis (ON), autoimmune optic neuropathy, and leber hereditary optic neuropathy (LHON). This study suggested that after 9.6 ± 8.7 days, younger fetuses were affected by opthalmic-related adverse outcomes.<a class="elsevierStyleCrossRef" href="#bb0025"><span class="elsevierStyleSup">5</span></a></p><p id="p0025" class="elsevierStylePara elsevierViewall">In conclusion, the majority of populations tolerate the SARS-CoV-2 vaccination types well. However, there were some negative side effects, notably in people with neuromyelitis optica spectrum conditions, such as mild optic neuritis. The clinical advantages of receiving the COVID-19 vaccine far exceed the hazards. Optic neuritis has unique symptoms and, in the majority of cases, resolves on its own without special care. Therefore, more extensive research is required to address the true prevalence of ocular neuropathies linked to COVID-19 immunization.</p><span id="s0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="st0015">Conflict of interest</span><p id="p0030" class="elsevierStylePara elsevierViewall">Nil.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:2 [ 0 => array:2 [ "identificador" => "s0005" "titulo" => "Conflict of interest" ] 1 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bs0005" "bibliografiaReferencia" => array:18 [ 0 => array:3 [ "identificador" => "bb0005" "etiqueta" => "1." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Correcting COVID-19 vaccine misinformation: Lancet Commission on COVID-19 vaccines and therapeutics Task force members" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:11 [ 0 => "P. Hotez" 1 => "C. Batista" 2 => "O. Ergonul" 3 => "J.P. Figueroa" 4 => "S. Gilbert" 5 => "M. Gursel" 6 => "M. Hassanain" 7 => "G. Kang" 8 => "J.H. Kim" 9 => "B. Lall" 10 => "H. Larson" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:3 [ "tituloSerie" => "EClinicalMedicine." "fecha" => "2021" "paginaInicial" => "33" ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bb0010" "etiqueta" => "2." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Third booster vaccination and stopping the Omicron, a new variant of concern" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "K. Ghazvini" 1 => "M. Karbalaei" 2 => "M. Keikha" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.vacun.2022.05.005" "Revista" => array:7 [ "tituloSerie" => "Vacunas." "fecha" => "2022" "volumen" => "23" "paginaInicial" => "S103" "paginaFinal" => "S110" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/35818430" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S0140673614617748" "estado" => "S300" "issn" => "01406736" ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bb0015" "etiqueta" => "3." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:7 [ 0 => "S. Galmiche" 1 => "L.B. Nguyen" 2 => "E. Tartour" 3 => "X. de Lamballerie" 4 => "L. Wittkop" 5 => "P. Loubet" 6 => "O. Launay" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.cmi.2021.09.036" "Revista" => array:6 [ "tituloSerie" => "Clin Microbiol Infect" "fecha" => "2021" "volumen" => "28" "paginaInicial" => "163" "paginaFinal" => "177" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/35020589" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bb0020" "etiqueta" => "4." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A case with new-onset neuromyelitis optica spectrum disorder following COVID-19 mRNA BNT162b2 vaccination" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "I. Caliskan" 1 => "E. Bulus" 2 => "N. Afsar" 3 => "A. Altintas" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/NRL.0000000000000420" "Revista" => array:7 [ "tituloSerie" => "Neurologist" "fecha" => "2022" "volumen" => "27" "numero" => "3" "paginaInicial" => "147" "paginaFinal" => "150" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/35184119" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bb0025" "etiqueta" => "5." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "COVID-19 vaccine-associated optic neuropathy: a systematic review of 45 patients" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:7 [ 0 => "A.G. Elnahry" 1 => "M.Y. Al-Nawaflh" 2 => "A.A. Gamal Eldin" 3 => "O. Solyman" 4 => "A.B. Sallam" 5 => "P.H. Phillips" 6 => "A.M. Elhusseiny" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3390/vaccines10101758" "Revista" => array:6 [ "tituloSerie" => "Vaccines." "fecha" => "2022" "volumen" => "10" "numero" => "10" "paginaInicial" => "1758" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/36298623" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bb0030" "etiqueta" => "6." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Transient oculomotor palsy following the administration of the messenger RNA-1273 vaccine for SARS-CoV-2 diplopia following the COVID-19 vaccine" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "M.C. Pappaterra" 1 => "E.J. Rivera" 2 => "A.L. Oliver" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:2 [ "tituloSerie" => "J Neuroophthalmol" "fecha" => "2022" ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bb0035" "etiqueta" => "7." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Acute abducens nerve palsy following COVID-19 vaccination" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "D.P. Reyes-Capo" 1 => "S.M. Stevens" 2 => "K.M. Cavuoto" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:7 [ "tituloSerie" => "J Am Associat Pediatr Ophthalmol Strabismus" "fecha" => "2021" "volumen" => "25" "numero" => "5" "paginaInicial" => "302" "paginaFinal" => "303" "itemHostRev" => array:3 [ "pii" => "S0002870317302417" "estado" => "S300" "issn" => "00028703" ] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bb0040" "etiqueta" => "8." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Adverse event reporting and Bell's palsy risk after COVID-19 vaccination" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "C. Khouri" 1 => "M. Roustit" 2 => "J.L. Cracowski" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S1473-3099(21)00646-0" "Revista" => array:7 [ "tituloSerie" => "Lancet Infect Dis" "fecha" => "2021" "volumen" => "21" "numero" => "11" "paginaInicial" => "1490" "paginaFinal" => "1491" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/34717804" "web" => "Medline" ] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bb0045" "etiqueta" => "9." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Trends in optic neuritis incidence and prevalence in the UK and association with systemic and neurologic disease" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:9 [ 0 => "T. Braithwaite" 1 => "A. Subramanian" 2 => "A. Petzold" 3 => "J. Galloway" 4 => "N.J. Adderley" 5 => "S.P. Mollan" 6 => "G.T. Plant" 7 => "K. Nirantharakumar" 8 => "A.K. Denniston" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1001/jamaneurol.2020.3502" "Revista" => array:7 [ "tituloSerie" => "JAMA Neurol" "fecha" => "2020" "volumen" => "77" "numero" => "12" "paginaInicial" => "1514" "paginaFinal" => "1523" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/33017023" "web" => "Medline" ] ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bb0050" "etiqueta" => "10." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Neuro-ophthalmic implications of severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) related infection and vaccination" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "A. Petzold" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "The Asia-Pacific J Ophthalmol" "fecha" => "2022" "volumen" => "11" "numero" => "2" "paginaInicial" => "196" "paginaFinal" => "207" ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bb0055" "etiqueta" => "11." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "COVID-19 vaccine-associated optic neuritis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "W.J. Lee" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "QJM: An Int J Med" "fecha" => "2022" "volumen" => "115" "numero" => "10" "paginaInicial" => "683" "paginaFinal" => "685" ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bb0060" "etiqueta" => "12." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Case-centered analysis of optic neuritis after vaccines" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "R. Baxter" 1 => "E. Lewis" 2 => "B. Fireman" 3 => "F. DeStefano" 4 => "J. Gee" 5 => "N.P. Klein" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/cid/ciw224" "Revista" => array:7 [ "tituloSerie" => "Clin Infect Dis" "fecha" => "2016" "volumen" => "63" "numero" => "1" "paginaInicial" => "79" "paginaFinal" => "81" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27069066" "web" => "Medline" ] ] ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bb0065" "etiqueta" => "13." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A literature review on optic neuritis following vaccination against virus infections" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "J.P. Stübgen" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.autrev.2013.03.012" "Revista" => array:7 [ "tituloSerie" => "Autoimmun Rev" "fecha" => "2013" "volumen" => "12" "numero" => "10" "paginaInicial" => "990" "paginaFinal" => "997" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23541483" "web" => "Medline" ] ] ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bb0070" "etiqueta" => "14." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Optic neuropathy after COVID-19 vaccination: a report of two cases" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:11 [ 0 => "A.G. Elnahry" 1 => "Z.B. Asal" 2 => "N. Shaikh" 3 => "K. Dennett" 4 => "M.N. Abd Elmohsen" 5 => "G.A. Elnahry" 6 => "A. Shehab" 7 => "M. Vytopil" 8 => "L. Ghaffari" 9 => "G.K. Athappilly" 10 => "D.J. Ramsey" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ "tituloSerie" => "Int J Neurosci" "fecha" => "2021" "volumen" => "1-7" "itemHostRev" => array:3 [ "pii" => "S0735109710017444" "estado" => "S300" "issn" => "07351097" ] ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bb0075" "etiqueta" => "15." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "COVID-19 susceptibility and outcomes among patients with neuromyelitis optica spectrum disorder (NMOSD): A systematic review and meta-analysis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:8 [ 0 => "M. Barzegar" 1 => "O. Mirmosayyeb" 2 => "N. Ebrahimi" 3 => "S. Bagherieh" 4 => "A. Afshari-Safavi" 5 => "A.M. Hosseinabadi" 6 => "V. Shaygannejad" 7 => "N. Asgari" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:3 [ "tituloSerie" => "Mult Scler Relat Disord" "fecha" => "2022" "volumen" => "57" ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bb0080" "etiqueta" => "16." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Nonarteritic anterior ischemic optic neuropathy following COVID-19 vaccination: consequence or coincidence" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "R. Tsukii" 1 => "Y. Kasuya" 2 => "S. Makino" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ "tituloSerie" => "Case Rep Ophthalmol Med" "fecha" => "2021" "paginaInicial" => "2021" "itemHostRev" => array:3 [ "pii" => "S0735109717367165" "estado" => "S300" "issn" => "07351097" ] ] ] ] ] ] ] 16 => array:3 [ "identificador" => "bb0085" "etiqueta" => "17." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Post vaccination optic neuritis: Observations from the SARS-CoV-2 pandemic" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:11 [ 0 => "L.M. Alvarez" 1 => "Y. Ning Neo" 2 => "I. Davagnanam" 3 => "M. Ashenhurst" 4 => "J. Acheson" 5 => "A. Abdel-Hay" 6 => "D. Alshowaeir" 7 => "M. Bakheet" 8 => "O. Balaguer" 9 => "R. Batra" 10 => "T. Braithwaite" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Libro" => array:1 [ "fecha" => "2022" ] ] ] ] ] ] 17 => array:3 [ "identificador" => "bb0090" "etiqueta" => "18." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Watch out for neuromyelitis optica spectrum disorder onset or clinical relapse after COVID-19 vaccination: what neurologists need to know?" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "S. Paybast" 1 => "A. Emami" 2 => "F. Baghalha" 3 => "A.N. Moghadasi" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:3 [ "tituloSerie" => "Mult Scler Relat Disord" "fecha" => "2022" "volumen" => "103960" ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/24451460/0000002400000002/v1_202305072301/S2445146023000274/v1_202305072301/en/main.assets" "Apartado" => array:4 [ "identificador" => "66708" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Special Article" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/24451460/0000002400000002/v1_202305072301/S2445146023000274/v1_202305072301/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2445146023000274?idApp=UINPBA00004N" ]
Year/Month | Html | Total | |
---|---|---|---|
2024 November | 1 | 0 | 1 |
2024 October | 2 | 0 | 2 |
2024 September | 4 | 0 | 4 |
2024 August | 1 | 0 | 1 |
2024 July | 4 | 0 | 4 |
2024 June | 2 | 0 | 2 |
2024 May | 2 | 0 | 2 |
2024 April | 1 | 0 | 1 |
2024 March | 4 | 0 | 4 |